Share:
The International Liver Congress (ILC 2022), convened by the European Association for the Study of the Liver (EASL), was held in London, UK on 22-26 June 2022. Check out the official website of the Congress.
Here are selected highlights from ILC 2022:
- WHO publishes updated guidance on hepatitis C infection – with new recommendations on treatment of adolescents and children, simplified service delivery and diagnostics (June 24)
- Health Policy Watch: Effective treatment and potential cure for hepatitis D; Results disclosed at International Liver Congress (June 23)
Pharma companies at ILC 2022:
- Assembly Biosciences presents new data highlighting clinical progress of HBV core inhibitor programs (ABI-H3733, ABI-4334 and vebicorvir) at EASL’s International Liver Congress™ 2022 (June 22)
- Vaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1 (June 22)
- Aligos Therapeutics presents 28-day safety, efficacy and pharmacokinetic clinical data for CAM drug candidate ALG-000184, first clinical data for NASH drug candidate ALG-055009 and nonclinical data in other chronic hepatitis B programs at the European Association for the Study of the Liver’s Digital International Liver Congress™ 2022 (June 22)
- Gilead Sciences: Treatment with Hepcludex® (bulevirtide) meets primary endpoint and achieves significant response in chronic hepatitis delta virus at 48 weeks (June 23)
- SCG Cell Therapy presents clinical proof-of-concept data at International Liver Congress (ILC) 2022 Annual Meeting (June 23)
- Vir Biotechnology announces new clinical data from its broad hepatitis B program, including results from ongoing trials of VIR-2218 and VIR-3434 (June 25)
- Arbutus presents new data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and provides AB-836 clinical update (June 25)
- Antios Therapeutics’ ATI-2173 demonstrates suppression of hepatitis B virus in Phase 2a study; ATI-1428 and ATI-1645 exhibit potent antiviral activity in a nonclinical study (June 25)
- Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic hepatitis B at the EASL International Liver Congress™ (June 25)
- GSK presents promising new data for bepirovirsen, an investigational treatment for chronic hepatitis B (June 25) (See also: Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™)
- Ascletis’ subcutaneous PD-L1 antibody ASC22 demonstrated potential of functional cure of chronic hepatitis B as 42.9% of patients with baseline HBsAg≤100 IU/mL obtained sustained HBsAg loss (June 25)
- Karolinska Development’s portfolio company Svenska Vaccinfabriken presents scientific advancements at international conference (June 27)
- Eiger BioPharmaceuticals announces results from multiple presentations on HDV at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022 (June 27)
- VBI Vaccines announces new long-term follow-up clinical data for its 3-antigen adult hepatitis B vaccine presented at EASL 2022 (June 28)
- BioSpace: Ascletis, Takeda, Arrowhead & more present new findings at EASL Liver Conference
- Contagion Live: GSK reports Phase 2b results on bepirovirsen for chronic hepatitis B treatment
infohep reports:
- People cured of hepatitis C remain at higher risk of death due to liver- and drug-related causes
- Short-course treatment prevents hepatitis C after organ transplant
- Re-treatment of hepatitis C is highly effective after the first combination fails
- Experimental hepatitis B combination suppresses key marker but fails to achieve functional cure
- Bulevirtide leads to sustained improvement for hepatitis D patients
- Bepirovirsen suppresses hepatitis B surface antigen, moves forward to larger functional cure studies
NATAP reports: click here to access all reports
Healio reports: click here to access all reports
MedPage Today reports: click here to access all reports
Medscape reports: click here to access all reports
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.